- Home
- EMD vs FULC Comparison
EMD vs FULC Comparison
Compare EMD & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMD | FULC |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 645.2M | 718.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | EMD | FULC |
|---|---|---|
| Price | $11.02 | $8.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | 229.4K | ★ 708.9K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.56 | $2.32 |
| 52 Week High | $11.30 | $15.74 |
Technical Indicators
Market Signals| Indicator | EMD | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 49.92 | 34.40 |
| Support Level | $10.22 | $6.33 |
| Resistance Level | $11.30 | $8.50 |
| Average True Range (ATR) | 0.12 | 0.84 |
| MACD | -0.03 | -0.25 |
| Stochastic Oscillator | 33.33 | 2.65 |
Price Performance
Historical ComparisonAbout EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management, and long term investment company. The primary investment objective of the company is to seek high current income and the secondary objective is to seek capital appreciation.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.